

**Activity Outline**  
**FDA Drug Topics: Fraudulent Products – Hidden Ingredients and Unproven Claims in Products Marketed as Dietary Supplements**  
**November 16, 2021**  
**FDA**

**Activity Coordinator:**  
Thanh Tam Nguyen-Chu (thanh.nguyen-chu@fda.hhs.gov), Kara Burke (Kara.Burke@fda.hhs.gov), Kimberly DeFronzo (Kimberly.Defronzo@fda.hhs.gov),

### **Series Description**

FDA's Division of Drug Information in the Center for Drug Evaluation and Research (CDER) sponsors a series of educational webinars targeting the needs of health care professionals and students. The webinars cover a broad range of FDA drug regulation and medication safety topics. These focused webinars support FDA's mission of promoting and protecting public health through interaction and education to strengthen current and future partnerships and relationships with clinicians and researchers.

### **Lecture Description**

Products marketed as dietary supplements that contain hidden, harmful ingredients and/or falsely claim to prevent, treat, mitigate, diagnose or cure disease continue to be a public health concern. As the marketplace for dietary supplements has evolved, so has the marketplace for the illegal sale of these adulterated products which contain ingredients ranging from prescription drugs to controlled substances. Furthermore, some companies may prey on vulnerable populations or exploit public health emergencies with unproven claims regarding their dietary supplements. The goal of this presentation is to increase awareness of this public health issue, provide an overview of the steps FDA is taking to protect consumers from fraudulent products marketed as supplements, and provide resources and the means which the public can report issues related to these types of products.

### **References**

- FDA, FTC Warn 10 Companies Illegally Selling Dietary Supplements Claiming to Treat Diabetes:  
<https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-10-companies-illegally-selling-dietary-supplements-claiming-treat-diabetes>
- Watch Out for False Promises on Some Dietary Supplements:  
<https://www.fda.gov/consumers/consumer-updates/watch-out-false-promises-some-dietary-supplements>
- Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments:  
<https://www.fda.gov/consumers/consumer-updates/beware-fraudulent-coronavirus-tests-vaccines-and-treatments>
- FDA Warns Consumers to Avoid Certain Male Enhancement and Weight Loss Products Sold Through Amazon, eBay and Other Retailers Due to Hidden, Potentially Dangerous Drug Ingredients:  
<https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-avoid-certain-male-enhancement-and-weight-loss-products-sold-through-amazon-ebay>
- Some Imported Dietary Supplements and Nonprescription Drug Products May Harm You:  
<https://www.fda.gov/consumers/consumer-updates/some-imported-dietary-supplements-and-nonprescription-drug-products-may-harm-you>

### **Series Objectives**

- Explain how to utilize FDA's Drug Information, medication safety resources, and regulatory guidances to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.

**Learning Objectives** After completion of this activity, the participant will be able to:

- Define the health hazards associated with fraudulent products
- Identify the product categories where tainted products are most commonly found
- Describe one of the regulatory challenges associated with fraudulent products
- Summarize how fraudulent products or adverse events related to such products are reported

### **Target Audience**

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, Certified Public Health (CPH), and physician assistants.

### **Agenda**

**Lecture 1 November 16, 2021**

| Time           | Topic  | Speaker                           |
|----------------|--|-----------------------------------|
| 1:00 - 2:00 PM | Fraudulent Products – Hidden Ingredients and Unproven Claims in Products Marketed as Dietary Supplements | Nicole Kornspan<br>Calvin Edwards |

### Continuing Education Accreditation



In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

### CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-037-L04-P, and ACPE Universal Activity Number JA0002895-0000-21-037-L04-T for 1.00 contact hour(s).

### CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

### AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

### CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

### Requirements for Receiving CE Credit

**Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME:** participants must attest to their attendance and complete the final activity evaluation via the CE Portal ([ceportal.fda.gov](http://ceportal.fda.gov)). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

**Attention Pharmacists and Pharmacy Techs:** Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

**Important Note regarding completion of evaluations and receiving credit**

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

**Disclosure**

**Faculty**

- ▣ Edwards, Calvin, Health Fraud Investigator, FDA/ORA/OPOP/OSPOP/DE/HFB *nothing to disclose*
- ▣ Kornspan, Nicole, Consumer Safety Officer, FDA *nothing to disclose*

**Planning Committee**

- ▣ Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI *nothing to disclose*
- ▣ Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV *nothing to disclose*
- ▣ DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI *nothing to disclose*
- ▣ Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI *nothing to disclose*
- ▣ Nguyen-Chu, Thanh Tam, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI *nothing to disclose*
- ▣ Paraoan, Dianne, MPH, RN, Associate Director for Regulatory Affairs, FDA/ CDER/ OMP *nothing to disclose*
- ▣ Rama, Kapoor, MD, Medical Officer, FDA *nothing to disclose*

**CE Consultation and Accreditation Team**

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

**Registration Fee and Refunds**

Registration is complimentary, therefore refunds are not applicable.